Advertising compliance for aesthetic practice in the UK
What UK advertising law and the CAP Code permit when promoting injectable treatment, why prescription-only medicines cannot be advertised, and what enforcement looks like.
Most marketing guidance written for aesthetic practice treats compliance as a footnote. In the United Kingdom it is the governing constraint, and it applies before any question of channel, audience or copy. The single fact that determines everything else is that botulinum toxin is a prescription-only medicine.
The two instruments
CAP Code rule 12.12 provides that prescription-only medicines, and treatments involving them, may not be advertised to the public. It applies to marketing communications in every medium the Code covers and is enforced by the Advertising Standards Authority.
Regulation 284 of the Human Medicines Regulations 2012 carries the underlying statutory prohibition on advertising prescription-only medicines to the general public. Because it is legislation rather than a self-regulatory code, the exposure is not limited to an adverse ruling. The Medicines and Healthcare products Regulatory Agency is the enforcing body, and reporting CAP and the MHRA have issued a joint enforcement notice to the beauty and cosmetic services industry, and the ASA has moved to targeted monitoring of non-compliant posts, with referral to the MHRA or professional regulators where an advertiser will not comply.
The two instruments overlap but are not the same. A marketing communication can attract both an ASA ruling and separate regulatory attention from the MHRA arising from the same wording.
What this rules out
The prohibition covers the product, not merely the brand name. Removing a trade mark and substituting a generic description of the same prescription-only medicine does not resolve the problem. In practice this excludes naming the product in advertising copy, page titles, headings, image captions, alt text, hashtags, video captions and paid search keywords and ad text, along with before-and-after imagery presented as advertising for the medicine, promotional pricing, time-limited offers and package deals built around it. Patient testimonials that name the product are marketing communications like any other.
What is permitted
The distinction drawn in the published guidance is between advertising a medicine and advertising a service. A practice may advertise that a consultation is available, and may describe the clinician, the premises and the assessment process. Non-proprietary descriptions of the treatment category — most commonly “anti-wrinkle injections” — are the accepted route, provided the copy does not resolve into a promotion of the specific medicine by other means.
Editorial and educational material occupies a separate position from advertising, but the line is drawn by function rather than by label. Content that describes mechanism, risk and evidence behaves differently from content whose purpose is to sell a named product, and calling a page “information” does not change what it is doing.
What enforcement looks like
Sanctions are cumulative rather than alternative. An upheld ASA complaint results in a published ruling naming the advertiser, which remains publicly accessible and searchable. Paid search advertising can be removed in cooperation with search engines. Persistent non-compliance can lead to inclusion on a public list of non-compliant advertisers, referral to Trading Standards, and referral to the MHRA, where enforcement escalates through notices to the possibility of prosecution.
Why this sits in a clinical reference
The rule is not an arbitrary restriction on commercial speech. It exists because the decision to use a prescription medicine belongs to a prescriber assessing an individual patient, and public advertising works by generating demand for a named product before that assessment happens. The compliance requirement and the clinical position point the same way.
